Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randjeanfrancoismaisonMay 121 min readRated NaN out of 5 stars.https://pubmed.ncbi.nlm.nih.gov/40179522/
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosishttps://pubmed.ncbi.nlm.nih.gov/40467521/
Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activityhttps://pubmed.ncbi.nlm.nih.gov/40450523/
Comments